The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Model-based prediction of patient-specific residual disease levels for imatinib-treated chronic myeloid leukemia.
M. Loeffler
No relevant relationships to disclose
M. Horn
No relevant relationships to disclose
I. Glauche
No relevant relationships to disclose
M. C. Müller
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
A. Hochhaus
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
I. Roeder
No relevant relationships to disclose